Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

459
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
459
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

29
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
29
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

21
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
21
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

489
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
489

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence (AI)-Facilitated Analysis of Single-Image Tissue Doppler Signal to Characterize Right Ventricular Dysfunction.

Echocardiography (Mount Kisco, N.Y.)·2026
Same author

Establishing baseline global longitudinal strain values in heart transplant recipients.

The international journal of cardiovascular imaging·2025
Same author

A Delayed Approach to Ventricular Septal Defect Repair After Myocardial Infarction.

JACC. Case reports·2025
Same author

Teaching minimally invasive coronary artery bypass grafting: a structured framework for well tolerated adoption and training.

Current opinion in cardiology·2025
Same author

Teaching minimally invasive coronary artery bypass grafting: a structured framework for well tolerated adoption and training.

Current opinion in cardiology·2025
Same author

Socioeconomic Status in Large Heart Failure Trials: A Call to Action.

Circulation. Heart failure·2025

Related Experiment Video

Updated: Aug 28, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K

Renal Dysfunction in Patients with Left Ventricular Assist Device.

Lamees I El Nihum1,2, Nina Manian1,2, Priya Arunachalam1,2

  • 1Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US.

Methodist Debakey Cardiovascular Journal
|September 22, 2022
PubMed
Summary

Cardiorenal syndrome (CRS) involves complex heart and kidney interactions. Left ventricular assist devices (LVAD) significantly impact renal function in heart failure patients, particularly those with pre-existing kidney issues.

Keywords:
LVADleft ventricular assist devicerenal dysfunction

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K
A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

1.7K

Related Experiment Videos

Last Updated: Aug 28, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K
A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

1.7K

Area of Science:

  • Cardiology
  • Nephrology
  • Medical Devices

Background:

  • Late-stage heart failure and renal dysfunction frequently coexist, a condition known as cardiorenal syndrome (CRS).
  • Early understanding of CRS pathophysiology focused on reduced cardiac output and renal perfusion.
  • Recent evidence points to more complex mechanisms underlying CRS.

Purpose of the Study:

  • To review the pathogenesis of cardiorenal syndrome.
  • To examine the impact of preoperative renal dysfunction in patients undergoing left ventricular assist device (LVAD) implantation.
  • To elucidate the effects of LVAD implantation on postoperative renal function.

Main Methods:

  • Literature review focusing on cardiorenal syndrome.
  • Analysis of studies concerning left ventricular assist device (LVAD) implantation.
  • Examination of the interplay between cardiac and renal function post-LVAD.

Main Results:

  • Left ventricular assist devices (LVAD) influence both cardiac and renal function.
  • Preoperative renal dysfunction is a critical factor in LVAD patient outcomes.
  • The mechanisms of LVAD impact on renal function are complex and not fully understood.

Conclusions:

  • LVADs have a significant, multifaceted effect on renal function in heart failure patients.
  • Understanding the impact of LVADs on renal function is crucial for managing patients with cardiorenal syndrome.
  • Further research is needed to fully elucidate the complex mechanisms involved.